Studies on the development of novel pharmacotherapy for schizophrenia that regulates the glutamate receptors

点击翻译按钮获取中文摘要

To obtain further insight into the pathophysiology of and the development of a novel pharmacotherapy for schizophrenia with a special attention on the schizophrenia-like symptoms induced by NMDA type glutamate receptor antagonists that are resistant to the currently used antipsychotics, we have studied and added new findings on the molecular and cellular mechanisms underlying regulation of tissue and extracellular contents of D-serine that is required for the physiological functions of the NMDA receptor. We also advanced the processes of the genetically modified animals needed to clarify the mechanisms.